UNAIDS leader to resign next year after review voices “no confidence”
Michel Sidibé, executive director of UNAIDS, the agency overseeing the global response to the HIV/AIDS epidemic, will step down from his post in June 2019, the agency announced yesterday (13 December).
December 14, 2018 — SciDevNet
Complacency kills: Prevention cannot take a backseat while we scale up treatment coverage to #endAIDS
Unprecedented progress has happened in fight against AIDS globally, but formidable challenges remain. Are we making enough progress on HIV prevention, treatment and care, in communities and places where HIV incidence is likely to be higher?
December 11, 2018 — Social Post
Highlights of HIVR4P 2018
Collaboration, combination prevention, and choice were the maxims of HIVR4P in Madrid, Oct 21–25, where over 1400 delegates gathered to discuss biomedical HIV prevention approaches.
December 6, 2018 — Lancet HIV
Drug buyers’ clubs aim to tackle HIV prevention ‘crisis’
A new generation of drug buyers’ clubs like those set up at the height of the AIDS epidemic is seeking to combat a “crisis” in preventing new HIV infections by providing access to cheap generics of a breakthrough prophylactic.
December 3, 2018 — Reuters
Could your favourite birth control put you at risk of HIV?
We could be just months away from knowing whether Depo-Provera use is linked to a higher risk of HIV infection in women.
November 23, 2018 — Bhekisisa
HIV prevention pill ‘set up to fail’ in some African countries
The rollout of oral HIV pre-exposure prophylaxis (PrEP), a pill that prevents infection when taken daily, is not being managed well in parts of Africa.
November 14, 2018 — Africa Portal
Funding cuts threaten HIV prevention targets
HIV prevention research funding continued to decline in 2017 for the fifth consecutive year, driven largely by a five-year low in US public sector funding, according to a report released on Thursday at the HIV Research for Prevention conference in Madrid, Spain.
October 27, 2018 — Times
Scientists ‘Far from Discovering’ HIV Cure
The ability of the HIV virus to mutate all the time is proving to be the most outstanding stumbling block for scientists to get the much-awaited HIV cure, researcher Dr Zaza Ndhlovu, Africa Health Research Institute, South Africa has said.
October 26, 2018 — The Observer
The road to HIV cure; exploring HIV functional cure
As the world all over is looking forward to a day when scientists will announce that finally there’s a permanent HIV and AIDS cure, scientists at the HIV Research for Prevention Conference-HIVR4P- in Madrid, Spain, present evidence that shows how difficult it is to get a permanent HIV cure at the moment.
October 25, 2018 — MBC
Far more people may be using PrEP than we know, HIV prevention conference hears
Many more gay men and men who have sex with men (MSM) may be using pre-exposure prophylaxis (PrEP) than figures from demonstration projects and national rollouts suggest, Michelle Rodolph, technical officer for the World Health Organization, told the HIVR4P 2018 conference in Madrid in Spain.
October 24, 2018 — aidsmap
HIV prevention: Bridging the gap between research and impact
“It is not just about R&D but about R&D and D — research and development, and delivery. If you take anyone of those three letters out, we fail. Each of them is equally important.”
October 24, 2018 — Citizen News Service
300,000 people on PrEP globally, mostly in the USA and Africa
At least 309,525 people have started to take pre-exposure prophylaxis (PrEP) in 68 countries, but 71 percent of PrEP users are in North America, according to a global analysis presented to the HIVR4P conference in Madrid.
October 23, 2018 — aidsmap
HIV activists take to the stage at ‘Research 4 Prevention’ opening to demand continued funding of wider prevention research agenda
Just before Tony Fauci, M.D., director of the NIH’s National Institute of Allergies and Infectious Diseases (NIAID) took the stage to deliver his address to the crowd, several dozen people filed on the stage with signs that read: “Whose choice, our choice?” and “Dear NIAID, Fund Microbicides NOW!”
October 23, 2018 — The Body
Coming soon: news from HIVR4P 2018
The third HIV Research for Prevention conference (HIVR4P) in Madrid next week (21 to 25 October) will feature news from every aspect of HIV prevention. HIVR4P came from a merger between the HIV vaccine and HIV microbicides conferences, and the breadth of its coverage reflects this.
October 18, 2018 — aidsmap
The number of new HIV cases in India is falling but not fast enough and there’s a risk of resurgence
Recent data from the National AIDS Control Organisation shows that the number of new HIV cases in India has fallen significantly since the peak of the epidemic in India in 2005. However, the pace of decline has also slowed in recent years.
September 27, 2018 — Scroll.in
Funding fall a threat to global progress on HIV
HIV and AIDS funding cuts, as evidenced by research, is a new big threat to progress made in fighting the pandemic, Mitchell Warren of AVAC notes.
August 9, 2018 — MBC
“Funding fall a threat to global progress on HIV”-AVAC
HIV and AIDS funding cuts, as evidenced by research, is a new big threat to progress made in fighting the pandemic, Mitchell Warren of AVAC notes. Warren expressed worry following research results of funding presented at the International AIDS 2018 Conference in Amsterdam, the Netherlands, which show that globally funding on HIV has significantly gone down.
August 9, 2018 — mbc
Gilead said PrEP to prevent HIV was ‘not a commercial opportunity.’ Now it’s running ads for it
The commercial, aptly titled “I’m on the Pill,” is part of a marketing push ….It’s a big reversal for Gilead, just three years ago the company said using Truvada to prevent infection with the virus that causes AIDS did not represent a commercial opportunity.
August 7, 2018 — Forbes
Gilead said PrEP to prevent HIV was ‘not a commercial opportunity.’ Now it’s running ads for it
“I’m on the pill,” declares a transgender woman in an up-close shot featured in Gilead Science’s latest drug commercial. “But it’s not birth control,” says a young guy, with a smile, in another scene. The actors are touting Truvada, the only drug approved to prevent the transmission of HIV.
August 7, 2018 — Forbes
2020 AIDS meeting in Bay Area sparks early controversy
The 2020 International AIDS Conference (IAC) in San Francisco and Oakland is still two years away, but protests around it have already erupted, with activists objecting to US government policies as discriminatory.
July 26, 2018 — MedPage Today
Gaps in global HIV research funding threaten progress
Mitchell Warren, Executive Director at AVAC, toldMedPage Todaythat this funding crisis is not new, and people have been late in recognizing it.
July 25, 2018 — MedPage Today
On demand PrEP works as well as daily PrEP for men who have sex with men
Not a single gay man who took two HIV prevention pills before and after sex had contracted HIV within a year thereafter, new research has found.
July 24, 2018 — All Africa
Our best shot: South African HIV vaccine shows promise
The latest results from a small HIV vaccine trial taking place in South Africa have shown promise, revealing that people’s immune systems recognised the vaccine and responded strongly.
July 5, 2018 — Times Select
Man awarded $18.4 million after doctors canceled his HIV test because he ‘was not at risk’ – only for a test three years later to show he had the virus and it had progressed to AIDS
A federal jury in Boston has awarded $18.4 million to a man who said two doctors failed to test him for HIV, which later developed into AIDS. Sean Stentiford, 48, consented to an HIV test in 2007 because he was experiencing facial paralysis.
June 21, 2018 — Daily Mail
As an HIV prevention drug surged in Australia, condom use fell
Infection rates declined despite an rise in unprotected sex, suggesting widespread use of the drug may mitigate the effects of riskier behavior.
June 11, 2018 — New York Times
The man who says science blew its best shot at an HIV vaccine
To the mainstream scientific community, Dorman’s quest is quixotic at best, tilting at windmills made of glycoproteins and RNA. But Dorman, now a spry 80, hasn’t given up. He’s convinced that if the rest of the scientific community had joined him decades ago, millions of lives would have been saved. They still could be.
June 1, 2018 — Wired
The need for HIV vaccine awareness among Nigerians
The continued advances in treatment are delightful and hold optimism, even as scientists double efforts to find a vaccine or cure. But then some questions need to be asked; what is the level of awareness of persons living with HIV to the current efforts of finding either a preventive or a therapeutic vaccine?
May 22, 2018 — Posterity Media
Ugandan researchers join hunt for HIV vaccine
A team of Ugandan researchers will lead a six-year HIV vaccine research in East Africa in an effort to find an HIV vaccine.
May 18, 2018 — New Vision
Chasing a new way to prevent HIV: Passive immunization
After decades of intense effort, an effective vaccine against HIV is not on the horizon — and, some say, may never be possible. So some AIDS researchers are going passive. As in passive immunization.
April 18, 2018 — NPR
HIV researcher is new head of US public-health agency
HIV researcher Robert Redfield will lead the Centers for Disease Control and Prevention (CDC)…“I hope [that as CDC director] he would be able to maintain the commitment to evidence that has been the hallmark of his career to date,” says Mitchell Warren.
March 21, 2018 — Nature
A controversial AIDS researcher was just tapped to head the CDC
Robert Redfield’s decades of scientific work is “peerless,” said Health and Human Services Secretary Alex Azar in a statement released Wednesday. But others point to his checkered past, including allegations of scientific misconduct.
March 21, 2018 — Buzzfeed
Why We Cut Men
AVAC Executive Director Mitchell Warren argues for the use of voluntary medical male circumcision as one of the most powerful and cost-effective HIV prevention tools available.
March 19, 2018 — BBC World Servce
In the era of daily PrEP, feds may stop research funding gels, rings, and douches for HIV prevention
Precisely because of the overwhelming success in recent years of oral PrEP — which various large studies have found to prevent HIV by anywhere between 90 to 100 percent — that the future of the douche and other sorts of topically applied anti-HIV agents, such as gels and dissolvable films, all loosely termed “microbicides,” is suddenly up in the air, if not outright doomed.
March 1, 2018 — The Body
Groups Working to End AIDS Fear Losing Ground Under Trump
Advocates working to end the AIDS epidemic fear they may lose ground under the Trump administration after coming within reach of ending the disease’s siege in the US and abroad.
February 27, 2018 — The Hill
Promising HIV Vaccines Could Stall Without Coordinated Research
Several vaccines and drugs for preventing the spread of HIV are showing signs of success in clinical trials, three decades after scientists began the search. But some researchers fear that progress will stall without a coordinated strategy to ensure that the most promising therapies to prevent infection win support from policymakers and reach the people who need them.
February 27, 2018 — Nature
→ Continue through the archives. Find articles from 2017 and older.